MDAI Spectral AI, Inc. Class A Common Stock Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
12:29
Jan 05
Jan 05
DeepView data moat with FDA catalyst while stock distressed
Spectral AI's DeepView uses discriminative AI on a proprietary 340-billion-datapoint wound database to predict burn healing with >80% accuracy on day one versus 60-70% for standard care, which can cut 14-21 day observation stays costing $3,000-$5,000/day. The stock trades as a distressed asset despite 18 months of runway, and the pending FDA De Novo decision (applied June 2025, likely Q1-early Q2 2026) is the central catalyst. Main stated risks are current financial optics/declining R&D revenue and potential FDA timeline extension.
HIGH
About MDAI Investor Commentary
Across the available history and selected sources, Buzzberg tracks MDAI (Spectral AI, Inc. Class A Common Stock) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Beowein.